Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives $41.00 Consensus PT from Analysts

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) have been assigned a consensus rating of “Hold” from the five analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $41.00.

A number of analysts have issued reports on the company. Craig Hallum boosted their target price on Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Zacks Research lowered Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. HC Wainwright lifted their price objective on Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. Finally, B. Riley Financial increased their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, March 20th.

Insider Activity

In related news, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at approximately $1,624,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Krempa sold 42,797 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the sale, the insider owned 25,249 shares in the company, valued at approximately $843,064.11. This trade represents a 62.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ETON. Soleus Capital Management L.P. acquired a new stake in Eton Pharmaceuticals in the second quarter valued at $4,061,000. Millennium Management LLC boosted its position in shares of Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after acquiring an additional 217,042 shares in the last quarter. Oberweis Asset Management Inc. acquired a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth about $4,180,000. BNP Paribas Financial Markets boosted its position in shares of Eton Pharmaceuticals by 162.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 229,790 shares of the company’s stock worth $4,993,000 after acquiring an additional 142,094 shares in the last quarter. Finally, EcoR1 Capital LLC increased its holdings in shares of Eton Pharmaceuticals by 7.0% in the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after acquiring an additional 141,394 shares during the last quarter. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Stock Up 0.5%

Shares of ETON opened at $37.51 on Friday. The company’s 50-day moving average price is $32.85 and its 200 day moving average price is $24.10. Eton Pharmaceuticals has a 12-month low of $13.76 and a 12-month high of $38.62. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62. The firm has a market cap of $1.03 billion, a P/E ratio of -535.78 and a beta of 0.86.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The company had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. On average, sell-side analysts forecast that Eton Pharmaceuticals will post 0.75 earnings per share for the current year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.